EGFR-Mutated Advanced NSCLC: Enhancing Treatment Strategies and Patient Care With Novel Therapies : Episode 4
Patient-Centered Approaches in EGFR-Mutated NSCLC
Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Video content above is prompted by the following:
- From your perspective, how have oral and subcutaneous therapies changed the quality of life for patients with EGFR-mutated NSCLC?
- What benefits have patients shared with you about their experiences with these newer administration routes?
- Looking ahead in EGFR-mutated NSCLC treatment, what developments are you most excited about?
- Please highlight any trials, novel agents, or combinations you find promising.
- How do you see the role of the multidisciplinary care team evolving as these therapies advance?
- As patients take more charge of their care, how do you see the role of patient empowerment and self-management evolving?
- What strategies have you found effective in supporting patients to take a more active role in their treatment journey?
- How do you balance the benefits of home-based care with ensuring patients feel supported and connected to their health care team?
Recent Videos
Related Content
